Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rockland Immunochemicals has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies 'Biosimilars' for the treatment of cancer.
Subscribe to our email newsletter
Rockland is expected to construct vectors of some of the anti-cancer drugs Herceptin, Rituxan, Zevalin and Erbitux to accelerate the development of the generic version of these antibodies.
Rockland Immunochemicals president Jim Fendrick said that Rockland’s antibody technology platform continues to be widely received by the research and biopharma community.
"We anticipate success in our antibody efforts to discover and develop both new and existing antibody targets that have application in the research, diagnostic and therapeutic markets," Fendrick said.